Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Immune System Key Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT04365179
- Locations
- 🇺🇸
University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Immune System Key Ltd
- Registration Number
- NCT03634150
- Locations
- 🇮🇱
Oncologic Institue, Kaplan, Reẖovot, Israel
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Immune System Key Ltd
- Registration Number
- NCT03059615
- Locations
- 🇮🇱
Kaplan Medical Center, Reẖovot, Israel
🇮🇱Rabin Medical Center, Petach Tikva, Israel
Phase 1 Trial of Intravenously Administered Nerofeâ„¢ in Subjects With Advanced Malignancies
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Immune System Key Ltd
- Target Recruit Count
- 23
- Registration Number
- NCT01690741
- Locations
- 🇮🇱
Kaplan Medical Center, Rehovot, Israel
© Copyright 2024. All Rights Reserved by MedPath